Nitazoxanide: Clinical studies of a broad-spectrum anti-infective agent

Future Microbiology

Volumn 2, Issue 6, 2007, Pages 583-590

  Aslam, Saima ^a,b   Musher, Daniel M ^a,b  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Clinical trials; Cryptosporidium; Giardia; Nitazoxanide

Indexed keywords

ALBENDAZOLE; ANTIPARASITIC AGENT; COTRIMOXAZOLE; MEBENDAZOLE; NITAZOXANIDE; PLACEBO; PRAZIQUANTEL; QUINFAMIDE; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ACQUIRED IMMUNE DEFICIENCY SYNDROME; AMEBIASIS; ANAEROBIC BACTERIUM; ANTHELMINTIC ACTIVITY; ANTIBACTERIAL ACTIVITY; ANTIMICROBIAL THERAPY; ANTIPROTOZOAL ACTIVITY; ARTICLE; ASCARIASIS; ASCARIS LUMBRICOIDES; BACTERIAL INFECTION; BLASTOCYSTIS HOMINIS; CESTODIASIS; CLINICAL STUDY; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM PARVUM; DIARRHEA; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FASCIOLA HEPATICA; FASCIOLIASIS; GASTROINTESTINAL SYMPTOM; GIARDIA LAMBLIA; GIARDIASIS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HYMENOLEPIS NANA; INTESTINE FLORA; INTESTINE INFECTION; MONOTHERAPY; NAUSEA; NEMATODIASIS; NONHUMAN; OFF LABEL DRUG USE; PHARMACODYNAMICS; PRIORITY JOURNAL; ROTAVIRUS; SHORT COURSE THERAPY; SINGLE DRUG DOSE; TAENIA SAGINATA; TAENIASIS; TRICHURIS; TRICHURIS TRICHURIA; VIRUS INFECTION; VOMITING;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIPARASITIC AGENTS; HUMANS; PARASITIC DISEASES; THIAZOLES;

CRYPTOSPORIDIUM; GIARDIA; GIARDIA INTESTINALIS; PROTOZOA; VERMES;

EID: 37549034628     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460913.2.6.583     Document Type: Article

References (35)

1. Rossignol JF, Cavier R: New derivative of 2-benzamido-5-nitrothiols. Chem. Abs. 83, 28216 (1975).
2. Fox, LM, Saravolatz LD: Nitazoxanide: a new thiazolide antiparasitic agent. Clin. Infect. Dis. 40(8), 1173-1180 (2005).
3. Musher DM, Logan N, Hamill RJ et al.: Nitazoxanide for the treatment of Clostridium difficile colitis. Clin. Infect. Dis. 43(4), 421-427 (2006).
4. Musher DM, Logan N, Mehendiratta V, Melgarejo NA, Garud S, Hamill RJ: Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide. J. Antimicrob. Chemother. 59(4), 705-710 (2007).
5. McVay, CS, Rolfe RD: In vitro and in vivo activities of nitazoxanide against Clostridium difficile. Antimicrob. Agents Chemother. 44(9), 2254-2258 (2000).
6. Rossignol JF, Abu-Zekry M, Hussein A, Santoro MG: Effect of nitazoxanide for treatment of severe rotavirus diarrhoea: randomised double-blind placebo-controlled trial. Lancet 368(9530), 124-129 (2006).
7. Rossignol JF, El-Gohary YM: Nitazoxanide in the treatment of vital gastroenteritis: a randomized double-blind placebo-controlled clinical trial. Aliment. Pharmacol. Ther. 24(10), 1423-1430 (2006).
8. Hoffman PS, Sisson G, Croxen MA et al.: Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductases of Helicobacter pylori, selected anaerobic bacteria and parasites, Campylobacter jijuni. Antimicrob. Agents Chemother. 51(3), 868-876 (2007).
9. Prescribing Information for Alinia™, Romark Laboratories, FL, USA (2005).
10. Stockis A, Deroubaix X, Lins R, Jean-Baptiste B, Calderon P, Rossignol JF: Pharmacokinetics of nitazoxanide after single oral dose administration in 6 healthy volunteers. Int. J. Clin. Pharmacol. Ther. 34(8), 349-351 (1996).
11. Broekhuysen J, Stockis A, Lins RL, De Graeve J, Rossignol JF: Nitazoxanide: pharmacokinetics and metabolism in man. Int. J. Clin. Pharmacol. Ther. 38(8), 387-394 (2000).
12. Stockis A, Allemon AM, De Bruyn S, Gengler C: Nitazoxanide pharmacokinetics and tolerability in man using single ascending oral doses. Int. J. Clin. Pharmacol. Ther. 40(5), 213-220 (2002).
13. Stockis A, De Bruyn S, Gengler C, Rosillon D: Nitazoxanide pharmacokinetics and tolerability in man during 7 days dosing with 0.5 g and 1 g b.i.d. Int. J. Clin. Pharmacol, Ther. 40(5), 221-227 (2002).
14. Doumbo O, Rossignol JF, Pichard E et al.: Nitazoxanide in the treatment of cryptosporidial diarrhea and other intestinal parasitic infections associated with acquired immunodeficiency syndrome in tropical Africa. Am. J. Trop. Med. Hyg. 56(6), 637-639 (1997).
15. Abdel-Maboud AI, Rossignol JF, el-Kady MS, Mostafa MS, Kabil SM: Cryptosporidiosis in Benha, study of some recent modalities in diagnosis and treatment. J. Egypt Soc. Parasitol. 30(3), 717-725 (2000).
16. Rossignol JF, Ayoub A, Ayers MS: Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized, double-blind, placebo-controlled study of nitazoxanide. J. Infect. Dis. 184(1), 103-106 (2001).
17. Amadi B, Mwiya M, Musuka J et al.: Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial. Lancet 360(9343), 1375-1380 (2002).
18. Rossignol JF: Nitazoxanide in the treatment of acquired immune deficiency syndrome-related cryptosporidiosis: results of the United States compassionate use program in 365 patients. Aliment. Pharmacol. Ther. 24(5), 887-894 (2006).
19. Rossignol JF, Hidalgo H, Feregrino M et al.: A double-blind placebo-controlled study of nitazoxanide in the treatment of cryptosporidial diarrhoea in AIDS patients in Mexico. Trans. R. Soc. Trop. Med. Hyg. 92(6), 663-666 (1998).
20. Rossignol JF, Kabil SM, el-Gohary Y, Younis AM: Effect of nitazoxanide in diarrhea and enteritis caused by Cryptosporidium species. Clin. Gastroenterol. Hepatol. 4(3), 320-324 (2006).
21. Hlavsa MC, Watson JC, Beach MJ: Giardiasis surveillance - United States, 1998-2002. MMWR 54(SS01), 9-16 (2005).
22. Rossignol JF, Ayoub A, Ayers MS: Treatment of diarrhea caused by Giardia intestinalis and Entamoeba histolytica or E. dispar: a randomized, double-blind, placebo-controlled study of nitazoxanide. J. Infect. Dis. 184(3), 381-384 (2001).
23. Ortiz JJ, Ayoub A, Gargala G, Chegne NL, Favennec L: Randomized clinical study of nitazoxanide compared to metronidazole in the treatment of symptomatic giardiasis in children from northern Peru. Aliment. Pharmacol. Ther. 15(9), 1409-1415 (2001).
24. Rossignol JF, Kabil SM, Said M, Samir H, Younis AM: Effect of nitazoxanide in persistent diarrhea and enteritis associated with Blastocystis hominis. Clin. Gastroenterol. Hepatol. 3(10), 987-991 (2005).
25. Juan JO, Lopez Chegne N, Gargala G, Favennec L: Comparative clinical studies of nitazoxanide, albendazole and praziquantel in the treatment of ascariasis, trichuriasis and hymenolepiasis in children from Peru. Trans. R. Soc. Trop. Med. Hyg. 96(2), 193-196 (2002).
26. Abaza H, E-ZA, Kabil SM, Rizk H: Nitazoxanide in the treatment of patients with intestinal protozoan and helmintbic infections: a report on 546 patients in Egypt. Curr. Ther. Res. 59, 116-121 (1998).
27. Romero Cabello R, Guerrero LR, Munoz Garcia MR, Geyne Cruz A: Nitazoxanide for the treatment of intestinal protozoan and helminthic infections in Mexico. Trans. R. Soc. Trop. Med. Hyg. 91(6), 701-703 (1997).
28. Davila-Gutierrez CE, Vasquez C, Trujillo-Hernandez B, Huerta M: Nitazoxanide compared with quinfamide and mebendazole in the treatment of helminthic infections and intestinal protozoa in children. Am. J. Trop. Med, Hyg. 66(3), 251-254 (2002).
29. Diaz E, Mondragon J, Ramirez E, Bernal R: Epidemiology and control of intestinal parasites with nitazoxanide in children in Mexico. Am. J. Trop. Med. Hyg. 68(4), 384-385 (2003).
30. Chero JC, Saito M, Bustos JA, Blanco EM, Gonzalvez G, Garcia HH: Hymenolepis nana infection: symptoms and response to nitazoxanide in field conditions. Trans. R. Soc. Trop. Med. Hyg. 101(2), 203-205 (2007).
31. Rossignol, JF, Maisonneuve H: Nitazoxmide in the treatment of Taenia saginata and Hymenolepis nana infections. Am. J. Trop. Med. Hyg. 33(3), 511-512 (1984),
32. Favennec L, Jave Ortiz J, Gargala G, Lopez Chegne N, Ayoub A, Rossignol JF: Double-blind, randomized, placebo-controlled study of nitazoxanide in the treatment of fascioliasis in adults and children from northern Peru. Aliment. Pharmacol. Ther. 17(2), 265-270 (2003).
33. Guttner Y, Windsor HM, Viiala CH, Dusci L, Marshall BJ: Nitazoxanide in treatment of Helicobacter pylori: a clinical and in vitro study. Antimicrob. Agents Chemother. 47(12), 3780-3783 (2003).
34. Zulu I, Kelly P, Njobvu L et al.: Nitazoxanide for persistent diarrhoea in Zambian acquired immune deficiency syndrome patients: a randomized-controlled trial. Aliment. Pharmacol. Ther. 21(6), 757-763 (2005).
35. Murphy JR, FJC: Pre-clinical toxicology of nitazoxanide - a new antiparasitic compound. J. Appl. Toxicol. 5(2), 49-52 (1985).